الفهرس 
Acute Lymphoblastic LeukemiaOnly 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
ABSTRACT
Background: LILRBs are immunological checkpoint factors because their immune-suppressive effect is comparable to that of CTLA4 and PD-1. LILRBs and a similar ITIM-containing receptor LAIR1 are expressed on and promote tumour growth in haematological and solid cancer cells. Aim: to measure serum LILRB 4 level in the peripheral blood of Egyptian patients with acute lymphoblastic leukaemia and correlating it with clinical outcome and prognosis of the disease. Subject and Methods: This study was conducted at Ain-Shams University Hospitals, division of Clinical Haematology and Oncology-department of Internal Medicine on 60 patients. Results: Serum LILRB4 level was statistically significant higher in ALL patients than healthy controls. LILRB4 serum level was statistically significant higher in patients who developed relapse than those who did not develop relapse. Serum LILRB4 level was statistically significant lower in patients who died than those who survived during induction. LILRB4 serum level was statistically significant higher in patients who died by ARDS and sepsis than those who died by COVID infection. Conclusion: LILRB4 level was statistically significant higher in ALL patients than healthy controls. ALL patients who received Dana-Farber protocol of treatment have statistically significant lower serum LILRB4 level than ALL patients who received hyper-CVAD and CALGB protocol